Osteolytic lesions occur rarely in patients with B-CLL and may respond well to ibrutinib

Leuk Lymphoma. 2016 Oct;57(10):2476-80. doi: 10.3109/10428194.2016.1151510. Epub 2016 Feb 25.

Affiliations

¹ a Department of Haematology and Medical Oncology , University Medicine Goettingen , Goettingen , Germany ;
² b Department of Pathology , University Medicine Goettingen , Goettingen , Germany ;
³ c Department of Diagnostic and Interventional Radiology , University Medicine Goettingen , Goettingen , Germany ;
⁴ d Department of Oncology and Haematology , University Cancer Center Hamburg (UCCH) , Hamburg , Germany.

PMID: 26916814
DOI: 10.3109/10428194.2016.1151510

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adenine / analogs & derivatives
Adult
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / complications
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Male
Osteolysis, Essential / drug therapy*
Osteolysis, Essential / etiology
Osteolysis, Essential / pathology
Piperidines
Pyrazoles / therapeutic use*
Pyrimidines / therapeutic use*
Treatment Outcome

Substances

Piperidines
Pyrazoles
Pyrimidines
ibrutinib
Adenine